LIGAND PHARMACEUTICALS (LGND) Stock Fundamental Analysis
USA - NASDAQ:LGND - US53220K5048 - Common Stock
186.66 USD
-0.08 (-0.04%)
186 USD
-0.66 (-0.35%)
Taking everything into account, LGND scores 5 out of 10 in our fundamental rating. LGND was compared to 191 industry peers in the Pharmaceuticals industry. LGND is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. LGND is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
LGND had positive earnings in the past year.
LGND had a positive operating cash flow in the past year.
In multiple years LGND reported negative net income over the last 5 years.
LGND had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With a decent Return On Assets value of -8.00%, LGND is doing good in the industry, outperforming 69.63% of the companies in the same industry.
With a decent Return On Equity value of -9.16%, LGND is doing good in the industry, outperforming 74.35% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8% | ||
| ROE | -9.16% | ||
| ROIC | N/A |
ROA(3y)0.61%
ROA(5y)1.2%
ROE(3y)0.46%
ROE(5y)1.58%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
LGND's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 93.05%, LGND belongs to the top of the industry, outperforming 95.29% of the companies in the same industry.
LGND's Gross Margin has been stable in the last couple of years.
LGND does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 93.05% |
OM growth 3Y-21.5%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.37%
GM growth 5Y0.62%
2. Health
2.1 Basic Checks
LGND does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LGND has more shares outstanding
The number of shares outstanding for LGND has been increased compared to 5 years ago.
Compared to 1 year ago, LGND has a worse debt to assets ratio.
2.2 Solvency
LGND has an Altman-Z score of 19.47. This indicates that LGND is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 19.47, LGND belongs to the top of the industry, outperforming 90.58% of the companies in the same industry.
LGND has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 19.47 |
ROIC/WACCN/A
WACC8.74%
2.3 Liquidity
LGND has a Current Ratio of 5.45. This indicates that LGND is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 5.45, LGND is doing good in the industry, outperforming 71.73% of the companies in the same industry.
A Quick Ratio of 5.21 indicates that LGND has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 5.21, LGND is in the better half of the industry, outperforming 70.68% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.45 | ||
| Quick Ratio | 5.21 |
3. Growth
3.1 Past
LGND shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.80%, which is quite impressive.
LGND shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.44% yearly.
Looking at the last year, LGND shows a very strong growth in Revenue. The Revenue has grown by 40.53%.
LGND shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.80% yearly.
EPS 1Y (TTM)20.8%
EPS 3Y-3.83%
EPS 5Y13.44%
EPS Q2Q%14.29%
Revenue 1Y (TTM)40.53%
Revenue growth 3Y-15.51%
Revenue growth 5Y6.8%
Sales Q2Q%14.68%
3.2 Future
The Earnings Per Share is expected to grow by 14.29% on average over the next years. This is quite good.
The Revenue is expected to grow by 20.16% on average over the next years. This is a very strong growth
EPS Next Y22.63%
EPS Next 2Y16.57%
EPS Next 3Y15.36%
EPS Next 5Y14.29%
Revenue Next Year31.46%
Revenue Next 2Y22.03%
Revenue Next 3Y20.53%
Revenue Next 5Y20.16%
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 30.90, the valuation of LGND can be described as expensive.
Compared to the rest of the industry, the Price/Earnings ratio of LGND indicates a somewhat cheap valuation: LGND is cheaper than 79.58% of the companies listed in the same industry.
LGND is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.77, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 24.06, the valuation of LGND can be described as rather expensive.
Based on the Price/Forward Earnings ratio, LGND is valued a bit cheaper than the industry average as 72.77% of the companies are valued more expensively.
LGND is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 23.23, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.9 | ||
| Fwd PE | 24.06 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of LGND indicates a somewhat cheap valuation: LGND is cheaper than 76.96% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of LGND indicates a somewhat cheap valuation: LGND is cheaper than 76.96% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 71.95 | ||
| EV/EBITDA | 159.94 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as LGND's earnings are expected to grow with 15.36% in the coming years.
PEG (NY)1.37
PEG (5Y)2.3
EPS Next 2Y16.57%
EPS Next 3Y15.36%
5. Dividend
5.1 Amount
LGND does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
186.66
-0.08 (-0.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners100.32%
Inst Owner Change-0.28%
Ins Owners1.69%
Ins Owner Change0.43%
Market Cap3.66B
Analysts84.62
Price Target186.79 (0.07%)
Short Float %5.86%
Short Ratio4.41
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.98%
Min EPS beat(2)7.61%
Max EPS beat(2)10.36%
EPS beat(4)4
Avg EPS beat(4)14.14%
Min EPS beat(4)4.63%
Max EPS beat(4)33.98%
EPS beat(8)8
Avg EPS beat(8)38.28%
EPS beat(12)12
Avg EPS beat(12)65.25%
EPS beat(16)15
Avg EPS beat(16)61.42%
Revenue beat(2)2
Avg Revenue beat(2)10.64%
Min Revenue beat(2)6.44%
Max Revenue beat(2)14.84%
Revenue beat(4)4
Avg Revenue beat(4)13.45%
Min Revenue beat(4)6.44%
Max Revenue beat(4)24.96%
Revenue beat(8)8
Avg Revenue beat(8)14.01%
Revenue beat(12)11
Avg Revenue beat(12)13.22%
Revenue beat(16)14
Avg Revenue beat(16)14.34%
PT rev (1m)0%
PT rev (3m)27.28%
EPS NQ rev (1m)0%
EPS NQ rev (3m)20.74%
EPS NY rev (1m)0.04%
EPS NY rev (3m)12.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)18.31%
Revenue NY rev (1m)0%
Revenue NY rev (3m)10.66%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.9 | ||
| Fwd PE | 24.06 | ||
| P/S | 19.5 | ||
| P/FCF | 71.95 | ||
| P/OCF | 69.58 | ||
| P/B | 4.42 | ||
| P/tB | 12.91 | ||
| EV/EBITDA | 159.94 |
EPS(TTM)6.04
EY3.24%
EPS(NY)7.76
Fwd EY4.16%
FCF(TTM)2.59
FCFY1.39%
OCF(TTM)2.68
OCFY1.44%
SpS9.57
BVpS42.27
TBVpS14.45
PEG (NY)1.37
PEG (5Y)2.3
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8% | ||
| ROE | -9.16% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 93.05% | ||
| FCFM | 27.11% |
ROA(3y)0.61%
ROA(5y)1.2%
ROE(3y)0.46%
ROE(5y)1.58%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)1.42%
ROCE(5y)2.25%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-21.5%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.37%
GM growth 5Y0.62%
F-Score5
Asset Turnover0.2
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 5.04% | ||
| Cap/Sales | 0.93% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 259.88% | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.45 | ||
| Quick Ratio | 5.21 | ||
| Altman-Z | 19.47 |
F-Score5
WACC8.74%
ROIC/WACCN/A
Cap/Depr(3y)71.95%
Cap/Depr(5y)50.12%
Cap/Sales(3y)19.71%
Cap/Sales(5y)12.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.8%
EPS 3Y-3.83%
EPS 5Y13.44%
EPS Q2Q%14.29%
EPS Next Y22.63%
EPS Next 2Y16.57%
EPS Next 3Y15.36%
EPS Next 5Y14.29%
Revenue 1Y (TTM)40.53%
Revenue growth 3Y-15.51%
Revenue growth 5Y6.8%
Sales Q2Q%14.68%
Revenue Next Year31.46%
Revenue Next 2Y22.03%
Revenue Next 3Y20.53%
Revenue Next 5Y20.16%
EBIT growth 1Y-288.32%
EBIT growth 3Y-33.67%
EBIT growth 5YN/A
EBIT Next Year478.11%
EBIT Next 3Y137.22%
EBIT Next 5Y79.19%
FCF growth 1Y-48.59%
FCF growth 3Y10.8%
FCF growth 5YN/A
OCF growth 1Y-51.27%
OCF growth 3Y7.19%
OCF growth 5YN/A